Home Blog of Signal Transduction Epigenetics AMPK The mitochondrial NADH shuttle system is a targetable vulnerability for Group 3 medulloblastoma in a hypoxic microenvironment

Category

Archives

Popular Post

ESKM, a novel therapeutic agent for sensitive and resistant PH+ leukemias

The mechanism of resistance to JAK2 inhibitor in myeloproliferative neoplasms patients

Effects of PARP inhibitors in BRCA gene-mutated ovarian cancer

DASATINIB; An inhibitor of Receptor Tyrosine Kinase

GP130/JAK/STAT3 signaling pathway induces multiple myeloma

The mitochondrial NADH shuttle system is a targetable vulnerability for Group 3 medulloblastoma in a hypoxic microenvironment

Medulloblastoma is a cancerous brain tumor that affects mostly children. Among the four groups defined by molecular characteristics, Group 3, the least well characterized, is also the least favorable, with a survival rate of 50%. Current treatments, based on surgery, radiotherapy, and chemotherapy, are not adequate and the lack of understanding of the different molecular features of Group 3 tumor cells makes the development of effective therapies challenging. In this study, the problem of medulloblastoma is approached from a metabolic standpoint in a low oxygen microenvironment. We establish that Group 3 cells use both the mitochondrial glycerol-3 phosphate (G3PS) and malate-aspartate shuttles (MAS) to produce NADH. Small molecules that target G3PS and MAS show a greater ability to decrease cell proliferation and induce apoptosis specifically of Group 3 cells. In addition, as Group 3 cells show improved respiration in hypoxia, the use of Phenformin, a mitochondrial complex 1 inhibitor, alone or in combination, induced significant cell death. Furthermore, inhibition of the cytosolic NAD+ recycling enzyme lactate dehydrogenase A (LDHA), enhanced the effects of the NADH shuttle inhibitors. In a 3D model using Group 3 human cerebellar organoids, tumor cells also underwent apoptosis upon treatment with NADH shuttle inhibitors. Our study demonstrates metabolic heterogeneity depending on oxygen concentrations and provides potential therapeutic solutions for patients in Group 3 whose tumors are the most aggressive.

 

Comments:

That's a fascinating study! It's encouraging to see research exploring different approaches to tackle medulloblastoma, especially in the context of Group 3 tumors, which have been challenging due to their molecular complexity and poorer prognosis.

The focus on metabolic pathways, particularly how Group 3 cells utilize different shuttles for NADH production in low oxygen environments, is intriguing. Targeting these specific pathways with small molecules appears to be a promising avenue for developing more effective therapies.

The findings regarding the use of inhibitors for G3PS and MAS to decrease cell proliferation and induce apoptosis in Group 3 cells, along with the impact of Phenformin and LDHA inhibition, highlight potential strategies for treatment. It's significant that these approaches show promise not just in cell cultures but also in 3D models using human cerebellar organoids, indicating potential relevance for clinical application.

The recognition of metabolic heterogeneity based on oxygen concentration and the subsequent identification of potential therapeutic solutions offer hope for improving outcomes in patients with Group 3 medulloblastoma. This study's insights could pave the way for more targeted and effective treatments for this aggressive form of brain cancer.

Related Products

Cat.No. Product Name Information
S2542 Phenformin HCl Phenformin HCl is a hydrochloride salt of phenformin that is an anti-diabetic drug from the biguanide class. It activates AMPK, increasing activity and phosphorylation.

Related Targets

AMPK